SPNC SEC-arkiveringar - Spectranetics Corp. (The)- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

789132

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Spectranetics Corp. (The)

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

February 13, 2018	SC 13G	SPNC / Spectranetics Corp. (The) / OAK RIDGE INVESTMENTS LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Spectranetics Corp (Name of Issuer) Common Stock (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
August 21, 2017	15-12G	Spectranetics 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-19711 THE SPECTRANETICS CORPORATION (Exact name of registrant as
August 21, 2017	15-12G	Spectranetics 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-19711 THE SPECTRANETICS CORPORATION (Exact name of registrant as
August 11, 2017	EX-4.1	THE SPECTRANETICS CORPORATION as Issuer WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee Second Supplemental Indenture Dated as of August 9, 2017 2.625% Convertible Senior Notes due 2034 SECOND SUPPLEMENTAL INDENTURE EX-4.1 Exhibit 4.1 THE SPECTRANETICS CORPORATION as Issuer and WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee Second Supplemental Indenture Dated as of August 9, 2017 2.625% Convertible Senior Notes due 2034 SECOND SUPPLEMENTAL INDENTURE SECOND SUPPLEMENTAL INDENTURE (this ?Second Supplemental Indenture?), dated as of August 9, 2017, between The Spectranetics Corporation, a Delaware corporation
August 11, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 8-K 1 d379373d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS 1 d445752ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No. 333-08489 Registration No. 333-117074 Registration No. 333-140022 Registration No. 333-145435 Registration No. 333-155282 Registration No. 333-163507 Registration No. 333-169455 Registration No. 333-169456 Registration No. 333-184112 Registration No. 333-184113 Registration N
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other juris
August 9, 2017	EX-3.2	SECOND AMENDED AND RESTATED THE SPECTRANETICS CORPORATION (the “Corporation”) ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF THE SPECTRANETICS CORPORATION (the ?Corporation?) ARTICLE I Stockholders Section 1.1. Annual Meetings. An annual meeting of stockholders shall be held for the election of directors at such date, time and place either within or without the State of Delaware as may be designated by the Board of Directors from time to time. Any other proper business m
August 9, 2017	EX-3.1	THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION THE SPECTRANETICS CORPORATION Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE SPECTRANETICS CORPORATION FIRST. The name of the corporation is The Spectranetics Corporation (the ? Company?). SECOND. The address of the Company?s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	S-8 POS	Spectranetics S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 9, 2017 Registration No.
August 9, 2017	SC 14D9/A	Spectranetics AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of
August 9, 2017	SC TO-T/A	Koninklijke Philips N.V SC TO-T/A SC TO-T/A 1 d438052dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING U
August 9, 2017	EX-99.(A)(5)(XXV)	Press Information EX-99.(A)(5)(XXV) Exhibit (a)(5)(xxv) Press Information August 9, 2017 Philips successfully completes tender offer for The Spectranetics Corporation Amsterdam, the Netherlands ? Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has successfully completed its previously announced tender offer (the ?Offer?) to purchase all outstanding shares of The S
August 8, 2017	10-Q	SPNC / Spectranetics Corp. (The) 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 0-19711 The Spect
August 3, 2017	8-K	Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IR
August 3, 2017	EX-99.1	Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million COLORADO SPRINGS, Colo. (August 3, 2017) - The Spectranetics Corporation (NASDAQ: SPNC) (?the Company?) today reported financial results for the three months ended June 30, 2017 . Highlights of the quarter, all compared with the three months ended June 30, 2016 , include: ? Revenue of $74.
July 28, 2017	SC TO-T/A	Koninklijke Philips N.V SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidia
July 28, 2017	EX-99.(A)(5)(XXIV)	AGREEMENT DATED 28 July 2017 CREDIT FACILITY relating to a Term Loan of €1,000,000,000 KONINKLIJKE PHILIPS N.V. ING BANK N.V. as Facility Agent Clause Page 1. Interpretation 1 1.1 Definitions 1 1.2 Construction 16 1.3 Dutch terms 18 1.4 No Personal L EX-99.(A)(5)(XXIV) Exhibit (a)(5)(xxiv) EXECUTION VERSION AGREEMENT DATED 28 July 2017 CREDIT FACILITY relating to a Term Loan of ?1,000,000,000 for KONINKLIJKE PHILIPS N.V. with ING BANK N.V. as Facility Agent CONTENTS Clause Page 1. Interpretation 1 1.1 Definitions 1 1.2 Construction 16 1.3 Dutch terms 18 1.4 No Personal Liability 19 2. The Facility 19 2.1 The Facility 19 2.2 Nature of a Finance
July 28, 2017	SC 14D9/A	Spectranetics 4D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of
July 27, 2017	SC 14D9/A	Spectranetics 4D9/A SC 14D9/A 1 sc14d9a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER S
July 27, 2017	EX-99.(A)(5)(XXIII)	Talking points EX-99.(A)(5)(XXIII) Exhibit (a)(5)(xxiii) Talking points July 27, 2017 Philips welcomes FDA approval of Spectranetics? Stellarex drug-coated balloon ? On July 26, 2017, The Spectranetics Corporation announced receipt of U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) of the Stellarex? drug-coated balloon (DCB), designed to restore and maintain blood flow to the superficial femora
July 27, 2017	SC TO-T/A	Koninklijke Philips N.V SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidia
July 26, 2017	SC 14D9/A	Spectranetics AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of
July 26, 2017	EX-99.1	FOR IMMEDIATE RELEASE Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon Stellarex produces top-tier clinical outcomes with a low drug dosage COLORADO SPRINGS, Colo., July 26, 2017 (GLOBE NEWSWIRE) -- The Spectranetics Corporation ex991stellarexpmapressre FOR IMMEDIATE RELEASE Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon Stellarex produces top-tier clinical outcomes with a low drug dosage COLORADO SPRINGS, Colo.
July 26, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 a2017stellarexpma8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other juri
July 26, 2017	CORRESP	Spectranetics ESP July 26, 2017 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 25, 2017	SC 14D9/A	Spectranetics AMENDMENT NO. 1 SC 14D9/A 1 sc14d9a.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Name of Person Filing Statement) COMMON STOCK, PAR VA
July 25, 2017	SC TO-T/A	Koninklijke Philips N.V SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidiary of KONI
July 18, 2017	SC TO-T/A	Koninklijke Philips N.V SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidia
July 12, 2017	SC 14D9	Spectranetics SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of
July 12, 2017	EX-99.(A)(1)(VI)	This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defi EX-99.(a)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below) and the related Letter of Transmittal (as defined below) and any amendments or supplements thereto. The Offer is not being made to (and no tenders will be accep
July 12, 2017	EX-99.(A)(1)(V)	Offer To Purchase For Cash All Outstanding Shares of Common Stock The Spectranetics Corporation $38.50 Net Per Share Pursuant to the Offer to Purchase dated July 12, 2017 HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA I EX-99.(a)(1)(v) Exhibit (a)(1)(v) Offer To Purchase For Cash All Outstanding Shares of Common Stock of The Spectranetics Corporation at $38.50 Net Per Share Pursuant to the Offer to Purchase dated July 12, 2017 by HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips N.V. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 1
July 12, 2017	EX-99.(A)(1)(II)	LETTER OF TRANSMITTAL To Tender Shares of Common Stock The Spectranetics Corporation $38.50 Net Per Share Pursuant to the Offer to Purchase dated July 12, 2017 HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a whol EX-99.(a)(1)(ii) Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of The Spectranetics Corporation at $38.50 Net Per Share Pursuant to the Offer to Purchase dated July 12, 2017 by HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips N.V. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDN
July 12, 2017	EX-99.(A)(1)(I)	Offer to Purchase for Cash All Outstanding Shares of Common Stock The Spectranetics Corporation $38.50 Net Per Share HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips EX-99.(a)(1)(i) Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of The Spectranetics Corporation at $38.50 Net Per Share by HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips N.V. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, O
July 12, 2017	EX-99.(D)(3)	[Remainder of page intentionally left blank] Page 8 of 11 The Spectranetics Corporation 9965 Federal Drive, Colorado Springs, CO 80921 Tel: 719-447-2000 • Fax: 719-447-2022 EX-99.(d)(3) Exhibit (d)(3) March 22, 2017 VIA E-MAIL Philips North America LLC 3000 Minuteman Road Andover, MA 01880 CONFIDENTIAL Ladies and Gentlemen: We understand that Philips North America LLC and its associated companies (the Recipient or you) desire to engage in certain discussions with The Spectranetics Corporation (the Company) in connection with your consideration of a possible neg
July 12, 2017	EX-99.(A)(1)(III)	NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock The Spectranetics Corporation $38.50 Net Per Share Pursuant to the Offer to Purchase dated July 12, 2017 HealthTech Merger Sub, Inc., a wholly owned subsidiary of Phil EX-99.(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY For Tender of All Outstanding Shares of Common Stock of The Spectranetics Corporation at $38.50 Net Per Share Pursuant to the Offer to Purchase dated July 12, 2017 by HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips N.V. THE OFFER AND WITHDRAWAL RI
July 12, 2017	EX-99.(A)(1)(IV)	Offer To Purchase For Cash All Outstanding Shares of Common Stock THE SPECTRANETICS CORPORATION $38.50 Net Per Share HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) Offer To Purchase For Cash All Outstanding Shares of Common Stock of THE SPECTRANETICS CORPORATION at $38.50 Net Per Share by HealthTech Merger Sub, Inc., a wholly owned subsidiary of Philips Holding USA Inc., a wholly owned subsidiary of Koninklijke Philips N.V. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, ON AUGUST 9, 2017
July 12, 2017	EX-99.(D)(2)	GUARANTEE AGREEMENT EX-99.(d)(2) Exhibit (d)(2) GUARANTEE AGREEMENT THIS GUARANTEE AGREEMENT (this ?Guarantee?), dated as of June 27, 2017, is made by KONINKLIJKE PHILIPS N.V., a corporation organized and existing under the laws of the Netherlands (the ?Guarantor?), in favor of THE SPECTRANETICS CORPORATION, a corporation organized under the laws of the State of Delaware (the ?Company?). PRELIMINARY STATEMENTS: WHERE
July 12, 2017	SC TO-T	Koninklijke Philips N.V SC TO-T SC TO-T 1 d425895dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (RULE 14d-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned
July 3, 2017	EX-99.2	SPNC ALL Exhibit 99.2 To: SPNC ALL From: Rob Fuchs, Sr. Vice President, Global Human Resources Re: Spectranetics ESPP Date: June 30, 2017 As you are aware, earlier this week, Spectranetics announced that it entered into a merger agreement with Royal Philips. The proposed transaction will not have any effect on the current ESPP purchase period, which will end and purchases will be made in the ordinary cours
July 3, 2017	EX-99.1	1 Exhibit 99.1 Transcript of Town Hall Meeting SCOTT DRAKE: Good morning, everybody. Standing room only. Team in the back, are we on? Are we live across the world? We are, good. So welcome. Welcome to our team here in Colorado Springs. Welcome to our teammates in Fremont. We will be seeing you right after this Town Hall and then we?ll make our way from Fremont to Maple Grove. We?ll see Maple Grove t
July 3, 2017	SC14D9C	Spectranetics SOLICITATION/RECOMMENDATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 8476
June 30, 2017	SC TO-C	Koninklijke Philips N.V SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidiary of KONINKLIJKE PHILIPS N.V. (Names of Filing Persons
June 30, 2017	EX-99.2	Excerpt of FAQ issued by Philips EX-99.2 Exhibit 99.2 Excerpt of FAQ issued by Philips Spectranetics / Philips merger: Frequently asked questions for NA Commercial team Selling questions Will Spectranetics? sales team be responsible for the sales of any Philips products? We expect that, following the closing of the transaction, both Philips and Spectranetics will cross-sell each other?s offerings. After the transaction closes, Sp
June 30, 2017	EX-99.3	LinkedIn Content EX-99.3 Exhibit 99.3 LinkedIn Content Philips acquires Spectranetics to expand minimally invasive intervention portfolio Philips has announced an agreement to acquire Spectranetics Corporation, a US-based leader in medical devices used in minimally invasive cardiovascular procedures. Image-guided therapy is a high-growth, high-innovation market driven by benefits for health systems and patients. U
June 30, 2017	EX-99.1	Excerpt of FAQ issued by Philips EX-99.1 Exhibit 99.1 Excerpt of FAQ issued by Philips Spectranetics FAQs About Spectranetics and the product How will Spectranetics support Philips? growth? Spectranetics, when combined with the current IGT Devices business, creates not only a highly synergistic therapy portfolio based on innovative and specialized physician preference products, but also a robust platform for growth. Given the ali
June 30, 2017	SC14D9C	Spectranetics SOLICITATION/RECOMMENDATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 8476
June 30, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisd
June 30, 2017	EX-2.1	Exhibit 4 (d) Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among THE SPECTRANETICS CORPORATION, PHILIPS HOLDING USA INC. and HEALTHTECH MERGER SUB, INC. Dated as of June 27, 2017 TABLE OF CONTENTS Page ARTICLE I The Transactions SECTION 1.01. The Offer 2 SECTION 1.02. Company Actions 5 SECTION 1.03. The Merger 6 SECTION 1.04. Closing 6 SECTION 1.05. Effective Time 6 SECTION 1.06. Merger Without Meeting of St
June 30, 2017	EX-99.1	Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease Exhibit 99.1 Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease ? Highly complementary addition to Philips? Image-Guided Therapy Business Group, strengthening its position in EUR 6+ billion market ? Spectranetics? strong device portfolio for vascular intervention and lead management procedures is
June 29, 2017	EX-99.6	Q&A issued by Philips EX-99.6 Exhibit 99.6 Q&A issued by Philips Media/investor Q&A Philips to acquire Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease Q1: Why is Philips acquiring Spectranetics? A1: The acquisition of Spectranetics will complement Philips? Image-Guided Therapy business, strengthen its position in a EUR 6+ billion market,
June 29, 2017	EX-99.5	Announcement posted on Philips’ internal website EX-99.5 Exhibit 99.5 Announcement posted on Philips? internal website Today we announced the signing of an agreement to acquire Spectranetics, a company that develops, manufactures, markets, and distributes medical devices used in minimally invasive procedures within the cardiovascular system. Welcoming Spectranetics to Philips gets us closer to the ultimate goal in the IGT Devices business: to en
June 29, 2017	EX-99.4	Announcement posted on Philips’ internal website EX-99.4 Exhibit 99.4 Announcement posted on Philips? internal website Expanding our presence in the image-guide therapy device space Philips has signed an agreement to acquire Spectranetics, a company that develops, manufactures, markets, and distributes medical devices used in minimally invasive procedures for cardiovascular diseases. At Philips, we are focused on improving people?s lives through
June 29, 2017	EX-99.3	Form of letter to certain Philips suppliers EX-99.3 Exhibit 99.3 Form of letter to certain Philips suppliers I wanted to make you aware that Philips signed an agreement to acquire Spectranetics, a company that develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The transaction is subject to the approval of shareholders of Spectranetics, regulatory approvals
June 29, 2017	EX-99.7	Press Release issued by Philips EX-99.7 Exhibit 99.7 Press Release issued by Philips Press Information June 29, 2017 Philips expands technology leadership in image-guided therapy with acquisition of CardioProlific Inc. Amsterdam, the Netherlands ? Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced the acquisition of CardioProlific Inc., a US-based, privately-held company that is developin
June 29, 2017	SC TO-C	Koninklijke Philips N.V SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidiary of KONINKLIJKE PHILIPS N.V. (Names of Filing Persons
June 29, 2017	EX-99.8	Transcript of Philips Investor Presentation Royal Philips Conference Call Wednesday, 28th June 2017 Royal Philips Conference Call Wednesday, 28th June 2017 Conference Call Pim Preesman Head of Investor Relations, Royal Philips Frans van Houten Chief EX-99.8 Exhibit 99.8 Transcript of Philips Investor Presentation Royal Philips Conference Call Wednesday, 28th June 2017 Royal Philips Conference Call Wednesday, 28th June 2017 Conference Call Pim Preesman Head of Investor Relations, Royal Philips Frans van Houten Chief Executive Officer, Royal Philips Abhijit Bhattacharya Chief Financial Officer, Royal Philips Bert van Meurs Business Group Leader
June 29, 2017	EX-99.1	Email to Philips’ employees EX-99.1 Exhibit 99.1 Email to Philips? employees Project Nike Deal Team, We are absolutely thrilled to share with you that, moments ago, we signed the agreement to acquire Spectranetics. This is a tremendous achievement and reflects months of your hard work. CONGRATULATIONS! Now, the fun begins! You will all play a critical role as we bring the Spectranetics team and Philips together, and we want
June 29, 2017	EX-99.2	Form of letter to certain Philips customers EX-99.2 Exhibit 99.2 Form of letter to certain Philips customers We are pleased to announce that Philips has signed an agreement to acquire Spectranetics, as of June 27, 2017. Spectranetics develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company?s products are available in over 65 countries and are used to
June 28, 2017	SC TO-C	Koninklijke Philips N.V SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company (Issuer)) HEALTHTECH MERGER SUB, INC. a wholly owned subsidiary of PHILIPS HOLDING USA INC. a wholly owned subsidiary of KONINKLIJKE PHILIPS N.V. (Names of Filing Persons
June 28, 2017	EX-99.3	Email to employees of Philips’ Image Guided Therapy Division, dated June 28, 2017 EX-99.3 Exhibit 99.3 Email to employees of Philips? Image Guided Therapy Division, dated June 28, 2017 Dear IGT and IGT Devices Leadership Teams: I am thrilled to share with you that Philips just signed an agreement to acquire Spectranetics, a medical device company based in Colorado Springs, Colorado, USA. This acquisition will become part of the IGT business group, and expands our IGT Devices pr
June 28, 2017	EX-99.4	Email to employees of Philips’ Image Guided Therapy Division, dated June 28, 2017. EX-99.4 Exhibit 99.6 Email to employees of Philips? Image Guided Therapy Division, dated June 28, 2017. Dear Team, We are very excited to share with you that we are expanding the Image Guided Therapy (IGT) family within Philips. Today, we signed an agreement to acquire Spectranetics, a global leader in vascular interventions and lead management solutions. Spectranetics is a U.S. medical device com
June 28, 2017	EX-99.5	Email to employees of Philips’ Image Guided Therapy Devices Division, dated June 28, 2017. EX-99.5 Exhibit 99.7 Email to employees of Philips? Image Guided Therapy Devices Division, dated June 28, 2017. Dear IGT Devices Team, To build on the note that Bert just sent to the entire organization, I am thrilled to announce that we will be expanding the IGT Devices family and merging with Spectranetics. Driven by our purpose: to enable healthcare providers to decide, guide, treat, and confir
June 28, 2017	EX-99.8	Email to employees of Philips’ North American Commercial Division, dated June 28, 2017 Announcement June 28, 2017 EX-99.8 Exhibit 99.10 Email to employees of Philips? North American Commercial Division, dated June 28, 2017 Announcement June 28, 2017 To: All IGT Sales Employees Commercial Team, We wanted to briefly follow up on the emails that you received earlier today from Bert and Chris to share our excitement about today?s news for our team. This announcement of our intention to acquire Spectranetics marks
June 28, 2017	EX-99.11	June, 2017 Page: 2 EX-99.11 Exhibit 99.21 Press Release issued by Philips, dated June 28, 2017 Press Information June 28, 2017 Philips executes next steps of its Capital Allocation strategy Amsterdam, the Netherlands ? Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will be initiating a share buyback program for an amount of up to EUR 1.5 billion. At the current share price, the buyback program represen
June 28, 2017	EX-99.1	Issued by Philips and Spectranetics EX-99.1 Exhibit 99.1 Issued by Philips and Spectranetics Press Information June 28, 2017 Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease ? Highly complementary addition to Philips? Image-Guided Therapy Business Group, strengthening its position in EUR 6+ billion market ? Spectranetics? strong
June 28, 2017	EX-99.6	Email to employees of Philips’ Peripheral Vascular Division, dated June 28, 2017. EX-99.6 Exhibit 99.8 Email to employees of Philips? Peripheral Vascular Division, dated June 28, 2017. PV team, I wanted to briefly follow up on the emails that you received earlier today from Bert and Chris[share.philips.com] to share my excitement about today?s news for our team. The announcement of our intention to acquire Spectranetics marks a key accomplishment for our peripheral vascular div
June 28, 2017	EX-99.2	Investor Presentation, dated June 28, 2017 EX-99.2 Exhibit 99.2 Investor Presentation, dated June 28, 2017 Philips announces agreement to acquire The Spectranetics Corporation Transaction Highlights June 28, 2017 Important information Additional Information The tender offer described in this communication (the ?Offer?) has not yet commenced, and this communication is neither an offer to purchase nor a solicitation of an offer to sell any s
June 28, 2017	EX-99.7	Email to employees of Philips’ Coronary Division, dated June 28, 2017 EX-99.7 Exhibit 99.9 Email to employees of Philips? Coronary Division, dated June 28, 2017 Coronary team, I wanted to briefly follow up on the emails that you received earlier today from Bert and Chris to share my excitement about today?s news for IGT Devices as a whole, as well as our coronary team. The announcement of our intention to acquire Spectranetics marks a key accomplishment for our all
June 28, 2017	EX-99.10	Employee Town Hall June 28, 2017 Philips and Spectranetics to merge EX-99.10 Exhibit 99.19 Presentation to Philips? employees, dated June 28, 2017 Employee Town Hall June 28, 2017 Philips and Spectranetics to merge a year by 2025 We?re aiming to improve the lives of three billion people Improving lives through meaningful innovation Who is Philips HealthTech? We are aiming to improve the Lives of 3 Billion people by 2025 Providing propositions for healthy living Su
June 28, 2017	EX-99.9	Dear teammates, EX-99.9 Exhibit 99.12 Dear teammates, Today has been quite an exciting day! With this morning?s announcement of Philips? intent to acquire Spectranetics, we look forward to our teams combining forces to expand our leadership position in image-guided therapy. Philips is a leading health technology company headquartered in Amsterdam. We are proud of our mission to provide broad solutions for patient
June 28, 2017	EX-99.9	Customer Letter Exhibit 99.9 Customer Letter June 28, 2017 Dear Valued Customer, I am pleased to share some exciting news. Spectranetics has reached an agreement to merge with Philips. Upon completion of the transaction, Spectranetics will be part of a dedicated, image-guided therapy (IGT) business group within Philips. As you may know, Philips is a leading health technology company headquartered in Amsterdam wit
June 28, 2017	EX-99.3	LM Commercial Sales Force Teammates Letter Template Exhibit 99.3 LM Commercial Sales Force Teammates Letter Template Dear LM Teammates, This morning, we announced that Spectranetics will be acquired by Philips, a leading health technology company. The transaction will unite two companies that have a shared view on the importance of culture, values, innovation and improving patients? lives around the world. A copy of the press release that was issue
June 28, 2017	EX-99.1	Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease Exhibit 99.1 Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease ? Highly complementary addition to Philips? Image-Guided Therapy Business Group, strengthening its position in EUR 6+ billion market ? Spectranetics? strong device portfolio for vascular intervention and lead management procedures is
June 28, 2017	SC14D9C	Spectranetics SOLICITATION/RECOMMENDATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 THE SPECTRANETICS CORPORATION (Name of Subject Company) THE SPECTRANETICS CORPORATION (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 8476
June 28, 2017	EX-99.7	Physician / Technician Letter Exhibit 99.7 Physician / Technician Letter June 28, 2017 Dear Physician Partner, I am pleased to share some exciting news. Spectranetics has reached an agreement to merge with Philips. Upon completion of the transaction, Spectranetics will be part of a dedicated, image-guided therapy (IGT) business group within Philips. As you may know, Philips is a leading health technology company headquartered
June 28, 2017	EX-99.4	International Commercial Sales Force Teammates Letter Exhibit 99.4 International Commercial Sales Force Teammates Letter Dear International Teammates, I am excited to announce that Spectranetics will be acquired by Philips, a leading health technology company. The transaction will unite two companies that have a shared view on the importance of culture, values, innovation and improving patients? lives around the world. A copy of the press release tha
June 28, 2017	EX-99.6	Supplier Letter Exhibit 99.6 Supplier Letter June 28, 2017 Dear Valued Supplier, I am pleased to share some exciting news. Spectranetics has reached an agreement to merge with Philips. Upon completion of the transaction, Spectranetics will be part of a dedicated, image-guided therapy (IGT) business group within Philips. As you may know, Philips is a leading health technology company headquartered in Amsterdam, wi
June 28, 2017	EX-99.10	Dear teammates, Exhibit 99.10 Dear teammates, Today has been quite an exciting day! With this morning?s announcement of Philips? intent to acquire Spectranetics, we look forward to our teams combining forces to expand our leadership position in image-guided therapy. Philips is a leading health technology company headquartered in Amsterdam. We are proud of our mission to provide broad solutions for patients and tr
June 28, 2017	EX-99.2	VI Commercial Sales Force Teammates Letter Template Exhibit 99.2 VI Commercial Sales Force Teammates Letter Template Dear VI Teammates, I am excited to announce that Spectranetics will be acquired by Philips, a leading health technology company. The transaction will unite two companies that have a shared view on the importance of culture, values, innovation and improving patients? lives around the world. A copy of the press release that was issued
June 28, 2017	EX-99.5	Teammate Letter Exhibit 99.5 Teammate Letter Dear Teammates, I am excited to announce that Spectranetics will be merging with Philips, a leading health technology company. The transaction will unite two companies that have a shared view on the importance of culture and values. Together, we will be a stronger company that is better able to serve teammates, patients and customers. A copy of the press release that w
June 28, 2017	EX-99.8	Distributor / Business Partner Letter Exhibit 99.8 Distributor / Business Partner Letter June 28, 2017 Dear Valued Business Partner, I am pleased to share some exciting news. Spectranetics has reached an agreement to merge with Philips. Upon completion of the transaction, Spectranetics will be part of a dedicated, image-guided therapy (IGT) business group within Philips. As you may know, Philips is a leading health technology company
June 14, 2017	EX-99.1	1 Spectranetics Announces Election of New Chairperson of the Board of Directors COLORADO SPRINGS, Colo. (June 14, 2017) - The Spectranetics Corporation (NASDAQ: SPNC) (“the Company”) announced today that B. Kristine Johnson has been elected as the ne ex991pressreleasechairpe 1 Spectranetics Announces Election of New Chairperson of the Board of Directors COLORADO SPRINGS, Colo.
June 14, 2017	8-K	Current Report Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS
June 14, 2017	8-K	Current Report 8-K 1 a2017shareholdermeetingvote.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or oth
June 9, 2017	EX-10.2	AMENDED AND RESTATED REVOLVING CREDIT AND SECURITY AGREEMENT dated as of June 9, 2017 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Bo EX-10.2 3 a17-150101ex10d2.htm EX-10.2 Exhibit 10.2 Execution Version AMENDED AND RESTATED REVOLVING CREDIT AND SECURITY AGREEMENT dated as of June 9, 2017 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FUNDING IV TRUST, as Agent and as a Lender, and THE ADDITION
June 9, 2017	EX-99.1	Spectranetics Announces $140 Million Debt Refinancing Strengthens Liquidity and Reduces Cost of Debt Exhibit 99.1 Spectranetics Announces $140 Million Debt Refinancing Strengthens Liquidity and Reduces Cost of Debt COLORADO SPRINGS, Colo. (June 9, 2017) - The Spectranetics Corporation (NASDAQ: SPNC) (the ?Company?) announced today that it has amended its existing credit facilities led by MidCap Financial and Silicon Valley Bank to increase the total senior secured facility to $140 million. The am
June 9, 2017	EX-10.1	AMENDED AND RESTATED TERM CREDIT AND SECURITY AGREEMENT dated as of June 9, 2017 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowe Exhibit 10.1 Execution Version AMENDED AND RESTATED TERM CREDIT AND SECURITY AGREEMENT dated as of June 9, 2017 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO ART
June 9, 2017	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2017 The Spectranetics Co UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-19711 (Commission File Nu
May 30, 2017	SD	Spectranetics SD 2016 Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 9965 Federal Drive Colorado Springs, Colorado 80921 (Address
May 30, 2017	EX-1.01	The Spectranetics Corporation Conflict Minerals Report For reporting period from January 1, 2016 to December 31, 2016 Exhibit Exhibit 1.01 The Spectranetics Corporation Conflict Minerals Report For reporting period from January 1, 2016 to December 31, 2016 I. Introduction This Conflict Minerals Report (the ?Report?) of The Spectranetics Corporation (the ?Company,? ?we,? ?us,? or ?our?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amend
April 28, 2017	DEF 14A	Spectranetics 2017 PROXY STATEMENT Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)
April 28, 2017	10-Q	Spectranetics 10-Q (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 27, 2017	EX-99.1	Spectranetics Reports First Quarter 2017 Revenue of $69.7 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Reports First Quarter 2017 Revenue of $69.7 million COLORADO SPRINGS, Colo. (April 27, 2017) - The Spectranetics Corporation (NASDAQ: SPNC) (?the Company?) today reported financial results for the three months ended March 31, 2017 . Highlights of the quarter, all compared with the three months ended March 31, 2016 , include: ? Revenue of $69
April 27, 2017	8-K	Results of Operations and Financial Condition 8-K 1 a20178kq1earningsrelease.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or othe
February 24, 2017	10-K	Spectranetics 10-K (Annual Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-19711 THE SPECTRANETICS CORPORAT
February 24, 2017	EX-10.100	Position: General Manager - Vascular Intervention Start Date: January 15, 2017 Reporting to: Scott Drake, Chief Executive Officer Compensation: You will be an exempt employee. Your gross bi-weekly salary will be $13,461.54 or $350,000.00 annually. An [Letterhead of The Spectranetics Corporation] December 24, 2016 Dear Scott: We are pleased to offer you the General Manager - Vascular Intervention position with the Spectranetics Corporation (the “Company,” “we,” or “us”) as a regular, full-time, exempt employee.
February 24, 2017	EX-10.99	Execution Version MidCap / Spectranetics / Amendment No. 1 to Credit Agreement (Revolving Loan) \\DC - 036639/000020 - 9343890 AMENDMENT NO. 1 TO REVOLVING CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO REVOLVING CREDIT AND SECURITY AGREEMENT ex1099amendmentno1torevo Execution Version MidCap / Spectranetics / Amendment No. 1 to Credit Agreement (Revolving Loan) \\DC - 036639/000020 - 9343890 AMENDMENT NO. 1 TO REVOLVING CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO REVOLVING CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 2nd day of December, 2016, by and among The Spectranetics Corporation, a Delaware corpo
February 24, 2017	EX-21.1	SUBSIDIARIES OF THE REGISTRANT THE SPECTRANETICS CORPORATION ANGIOSCORE INC. Jurisdiction: Delaware SPNC AUSTRALIA PTY LTD Jurisdiction: Australia SPECTRANETICS INTERNATIONAL B.V. Jurisdiction: The Netherlands SPECTRANETICS II B.V. Jurisdiction: The EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT THE SPECTRANETICS CORPORATION SUBSIDIARIES ANGIOSCORE INC. Jurisdiction: Delaware SPNC AUSTRALIA PTY LTD Jurisdiction: Australia SPECTRANETICS INTERNATIONAL B.V. Jurisdiction: The Netherlands SPECTRANETICS II B.V. Jurisdiction: The Netherlands Subsidiary of Spectranetics International B.V. SPECTRANETICS DEUTSCHLAND GMBH Jurisdiction: Germany Subsidiary o
February 24, 2017	EX-12.1	COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2016 2015 2014 2013 2012 Earnings (loss): (Loss) income before income taxes $ (57,333 ) $ (58,748 ) $ (41,223 ) $ 410 $ 2,960 Fixed charges to add to Exhibit 12.1 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2016 2015 2014 2013 2012 Earnings (loss): (Loss) income before income taxes $ (57,333 ) $ (58,748 ) $ (41,223 ) $ 410 $ 2,960 Fixed charges to add to earnings: Interest expense 12,219 6,883 3,546 58 63 Amortization of debt issuance costs 1,140 993 562 — — Rent interest factor (1) 977 9
February 23, 2017	8-K	Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission
February 23, 2017	EX-99.1	Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million COLORADO SPRINGS, Colo. (February 23, 2017) - The Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the three months and year ended December 31, 2016. Highlights of the quarter, all compared with the three months ended December 31, 2015, include: • Revenue of $7
February 15, 2017	SC 13G/A	SPNC / Spectranetics Corp. (The) / Visium Asset Management, LP - AMENDMENT TO FORM SC13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* The Spectranetics Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
February 13, 2017	SC 13G/A	SPNC / Spectranetics Corp. (The) / Arrowpoint Asset Management, LLC - 13G AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2017	SC 13G	SPNC / Spectranetics Corp. (The) / OAK RIDGE INVESTMENTS LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Spectranetics Corp (Name of Issuer) Common Stock (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
February 9, 2017	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Stacy McMahan, Paul Gardon, and Robert McCormack signing singly, the undersigned's true and lawful attorney-in-fact to: 1.
February 7, 2017	SC 13G	SPNC / Spectranetics Corp. (The) / FRANKLIN RESOURCES INC Passive Investment spec16in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 84760C107 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* THE SPECTRANETICS CORPORATION (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2016 (Date of E
January 24, 2017	8-K	Spectranetics 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (
January 24, 2017	EX-99.2	Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg-Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Stellarex DCB Disclo ex992zellerillumenateglo Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg-Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gou?ffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Stellarex DCB Disclosures Speaker Name: Prof. Thomas Zeller I have the following potential conflicts of interest to report: Consulting: Medtronic
January 24, 2017	EX-99.1	ILLUMENATE Global 12-month Results Validate Stellarex’s Top-tier Performance in Complex Patient Populations COLORADO SPRINGS, COLO. (January 24, 2017) – The Spectranetics Corporation (NASDAQ: SPNC), (“the Company”) today announced that Professor Thom ex991linciglobalpressrel ILLUMENATE Global 12-month Results Validate Stellarex?s Top-tier Performance in Complex Patient Populations COLORADO SPRINGS, COLO.
January 20, 2017	8-K	Current Report 8-K 1 spectranetics8k2017psu.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or othe
January 20, 2017	EX-10.1	1 THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT GRANT NOTICE The Spectranetics Corporation, a Delaware corporation (the “Company”), pursuant to The Spectranetics Corporation 2016 Incentive Award Plan (as it may be ame exhibit101spectranetics8 1 THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT GRANT NOTICE The Spectranetics Corporation, a Delaware corporation (the ?Company?), pursuant to The Spectranetics Corporation 2016 Incentive Award Plan (as it may be amended from time to time, the ?Plan?), hereby grants to the individual listed below (the ?Participant?) the following award of Performance Stock Units (?PSUs?).
January 11, 2017	EX-99.1	1 A LOOK AHEAD: 2017 35th Annual J.P. Morgan Healthcare Conference 2 Safe Harbor Statement This presentation contains forward‐looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange A jpmdeckv25finalcompatibi 1 A LOOK AHEAD: 2017 35th Annual J.P. Morgan Healthcare Conference 2 Safe Harbor Statement This presentation contains forward?looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not re
January 11, 2017	8-K	Spectranetics 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (
January 11, 2017	EX-99.1	Spectranetics Names Scott Hutton as General Manager, Vascular Intervention Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Names Scott Hutton as General Manager, Vascular Intervention COLORADO SPRINGS, COLO. (January 11, 2017) - The Spectranetics Corporation (NASDAQ: SPNC), (?the Company?) today announced that Scott Hutton has been named General Manager, Vascular Intervention, effective January 23 rd , 2017. In this role, Mr. Hutton will report directly to Scott
January 11, 2017	8-K	Current Report 8-K 1 a20178kscotthutton.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2017 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other ju
November 14, 2016	8-K	Regulation FD Disclosure 8-K 1 a20168-k110716.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisd
November 2, 2016	EX-99.1	Stellarex™ ILLUMENATE Pivotal Results are Top-tier in the Most Complex Patient Group Studied in DCB IDE Trials Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Stellarex? ILLUMENATE Pivotal Results are Top-tier in the Most Complex Patient Group Studied in DCB IDE Trials COLORADO SPRINGS, COLO. (November 2, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced that Dr. Sean Lyden pres ented the final 12-month results of the Stellarex Drug-coated Balloon (DCB) ILLUMENATE Pivotal Trial at the Transca
November 2, 2016	EX-99.3	1 Top-tier outcomes in the most complex patient population studied in DCB IDE trials Stellarex November 2, 2016 Exhibit 99.3 2 Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act o tctirpresentation 1 Top-tier outcomes in the most complex patient population studied in DCB IDE trials Stellarex November 2, 2016 Exhibit 99.
November 2, 2016	EX-99.2	ILLUMENATE Pivotal Stellarex DCB IDE Study 12-Month Results Sean Lyden, MD On behalf of Co-PI Prakash Krishnan, MD and the ILLUMENATE Pivotal Investigators Cleveland Clinic Cleveland, Ohio Disclosure Statement of Financial Interest • Grant/Research S lydentct2016illlumenatep ILLUMENATE Pivotal Stellarex DCB IDE Study 12-Month Results Sean Lyden, MD On behalf of Co-PI Prakash Krishnan, MD and the ILLUMENATE Pivotal Investigators Cleveland Clinic Cleveland, Ohio Disclosure Statement of Financial Interest ? Grant/Research Support ? Consulting Fees/Honoraria ? Other Financial Benefit ? Cook, Cordis, Gore, Endologix, Bolton, Silkroad, Trivascular, Medtronic, Spectranetics, Bard ? Spectranetics, Biomet, Endologix, TVA Medical ? VIVA Physicians Board Member Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.
November 2, 2016	8-K	Spectranetics 8-K TCT DATA RELEASE (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (
November 2, 2016	8-K	Spectranetics 8-K PMA SUBMISSION (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (
November 2, 2016	EX-99.1	Spectranetics Files PMA Application for FDA Approval of the Stellarex™ Drug-Coated Balloon Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Files PMA Application for FDA Approval of the Stellarex? Drug-Coated Balloon COLORADO SPRINGS, COLO. (November 2, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) announced today that it has submitted to the Food & Drug Administration (FDA) its Pre-Market Approval (PMA) application for the Stellarex drug-coated angioplasty balloon (DCB).
November 1, 2016	10-Q	Spectranetics 10-Q (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 27, 2016	8-K	Spectranetics 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (
October 27, 2016	EX-99.1	Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Reports Third Quarter 2016 Revenue of $68.3 million COLORADO SPRINGS, Colo. (October 27, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the three months ended September 30, 2016 . Highlights of the quarter, all compared with the three months ended September 30, 2015 , include: ? Revenue of $68.3 mil
September 12, 2016	SC 13G/A	SPNC / Spectranetics Corp. (The) / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) SPECTRANETICS CORP (Name of Issuer) COM (Title of Class of Securities) 84760C107 (CUSIP Number) August 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file
August 10, 2016	EX-99.2	ILLUMENATE European Randomized Clinical Trial: Prof. Dr. Marianne Brodmann 12-Month Final Results for the Stellarex DCB Division of Angiology, Medical University Graz, Austria On behalf of Dr. Henrik Schröder Jewish Hospital, Berlin, Germany Disclosu finalbrodmannillumenatee ILLUMENATE European Randomized Clinical Trial: Prof. Dr. Marianne Brodmann 12-Month Final Results for the Stellarex DCB Division of Angiology, Medical University Graz, Austria On behalf of Dr. Henrik Schr?der Jewish Hospital, Berlin, Germany Disclosures ? Consulting/Honoraria for ? Medtronic ? BARD ? Spectranetics ? Intact Vascular ? Avinger ? Soundbite Medical ? Rexgenero
August 10, 2016	EX-99.1	First Randomized Trial of the Stellarex™ Drug-coated Balloon Presented at the Amputation Prevention Symposium Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE First Randomized Trial of the Stellarex? Drug-coated Balloon Presented at the Amputation Prevention Symposium COLORADO SPRINGS, COLO. (August 10, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced that Professor Marianne Brodmann of Medical University Graz, Austria, presented the final 12-month results of the Stellarex Drug-coated Balloo
August 10, 2016	8-K	Spectranetics 8-K FINAL ILLUMENATE DATA (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (I
August 10, 2016	EX-99.1	Spectranetics Receives CE Mark for AngioSculptX™ Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Receives CE Mark for AngioSculptX? COLORADO SPRINGS, COLO. (August 10, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon Catheter. AngioSculptX is a first-of-its-kind device, combining the proven AngioSculpt PTCA scoring balloon catheter with a dru
August 10, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 a8-k2016angiosculptxcemark.htm 8-K ANGIOSCULPTX CE MARK UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 8
July 29, 2016	10-Q	Spectranetics 10-Q Q2 2016 (Quarterly Report) Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 29, 2016	EX-10.3	THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT GRANT NOTICE THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT GRANT NOTICE The Spectranetics Corporation, a Delaware corporation (the “Company”), pursuant to The Spectranetics Corporation 2016 Incentive Award Plan (as it may be amended from time to time, the “Plan”), hereby grants to the individual listed below (the “Participant”) the following award of Performance Stock Units (“PSUs”).
July 29, 2016	EX-10.6	THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE The Spectranetics Corporation, a Delaware corporation (the “Company”), pursuant to The Spectranetics Corporation 2016 Incentive Award Plan (as it may be amended from time to time, the “Plan”), hereby grants to the individual listed below (the “Participant”) the following award of Restricted Stock Units (“RSUs”).
July 29, 2016	EX-10.4	THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD AGREEMENT THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN RESTRICTED STOCK AWARD AGREEMENT The Spectranetics Corporation (the “Company”), pursuant to its 2016 Incentive Award Plan (the “Plan”), hereby grants an award of Restricted Stock to you, the Participant named below.
July 29, 2016	EX-10.5	THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT The Spectranetics Corporation, a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan (as it may be amended from time to time, the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s common stock, par value $0.
July 28, 2016	8-K	Spectranetics 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS
July 28, 2016	EX-99.1	Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million COLORADO SPRINGS, Colo. (July 28, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the three months ended June 30, 2016 . Highlights of the quarter, all compared with the three months ended June 30, 2015 , include: ? Revenue of $67.7 million increas
July 21, 2016	8-K	Spectranetics 8-K RULING AGAINST ANGIOSCORE (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS
July 21, 2016	EX-99.1	Federal Circuit Court Rules in Appeal Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Federal Circuit Court Rules in Appeal COLORADO SPRINGS, COLO. (July 21, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced that the United States Court of Appeals for the Federal Circuit reversed in part and affirmed in part trial court rulings in a case filed by its wholly-owned subsidiary, AngioScore Inc. against defendants Eitan Konst
July 15, 2016	CORRESP	Spectranetics ESP Document July 15, 2016 VIA EDGAR Kevin J. Kuhar Accounting Branch Chief Office of Electronics and Machinery U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: The Spectranetics Corporation Form 10-K for the Fiscal Year Ended December 31, 2015 Filed February 26, 2016 File No. 000-19711 Dear Mr. Kuhar: The Spectranetics Corporation (the ?Company?) is providing the
June 30, 2016	S-8	Spectranetics S-8 2016 ESPP Document As filed with the Securities and Exchange Commission on June 30, 2016 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 30, 2016	S-8	Spectranetics S-8 2016 INCENTIVE AWARD PLAN Document As filed with the Securities and Exchange Commission on June 30, 2016 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 23, 2016	8-K	Spectranetics 8-K 2016 PSU GRANT (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS
June 15, 2016	EX-10.2	THE SPECTRANETICS CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (as amended as of December 9, 2015) ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN Exhibit Exhibit 10.2 THE SPECTRANETICS CORPORATION 2010 EMPLOYEE STOCK PURCHASE PLAN (as amended as of December 9, 2015) ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1 Purpose and Scope . The purpose of this Spectranetics Corporation 2010 Employee Stock Purchase Plan (the ? Plan ?) is to assist employees of The Spectranetics Corporation and its Designated Subsidiaries in acquiring a
June 15, 2016	8-K	Spectranetics 8-K 2016 INCENTIVE AWARD PLAN & ESPP AMENDMENT (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2016 ( June 9, 2016 ) The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction
June 15, 2016	EX-10.1	THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN Exhibit Exhibit 10.1 THE SPECTRANETICS CORPORATION 2016 INCENTIVE AWARD PLAN 1. Purpose . The purpose of The Spectranetics Corporation 2016 Incentive Award Plan (the ?Plan?) is to attract and retain the best available personnel for positions of responsibility with the Company, to provide additional incentives to them and align their interests with those of the Company?s stockholders, and to thereb
June 13, 2016	8-K	Spectranetics 8-K 2016 SHAREHOLDER MEETING VOTE (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2016 ( June 9, 2016 ) The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction
June 7, 2016	8-K	Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS
May 27, 2016	SD	Spectranetics SD 2015 Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 9965 Federal Drive Colorado Springs, Colorado 80921 (Address
May 27, 2016	EX-1.01	The Spectranetics Corporation Conflict Minerals Report For reporting period from January 1, 2015 to December 31, 2015 Exhibit Exhibit 1.01 The Spectranetics Corporation Conflict Minerals Report For reporting period from January 1, 2015 to December 31, 2015 I. Introduction This Conflict Minerals Report (the ?Report?) of The Spectranetics Corporation (the ?Company,? ?we,? ?us,? or ?our?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amend
April 29, 2016	10-Q	SPNC / Spectranetics Corp. (The) 10-Q - Quarterly Report - 10-Q Q1 2016 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 0-19711 The Spec
April 28, 2016	8-K	Spectranetics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Emp
April 28, 2016	EX-99.1	Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million COLORADO SPRINGS, Colo. (April 28, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the three months ended March 31, 2016 . Highlights of the quarter, all compared with the three months ended March 31, 2015 , include: ? Revenue of $62.9 million incr
April 26, 2016	EX-99.2	Charing Cross 2016 Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg‐ Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study zellerillumenateglobalin Charing Cross 2016 Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg? Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gou?ffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Interim Analysis Charing Cross 2016 Disclosure Speaker name: Prof. Thomas Zeller ............................................
April 26, 2016	EX-99.1	12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics’ Stellarex drug-coated balloon at Charing Cross Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE 12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics? Stellarex drug-coated balloon at Charing Cross COLORADO SPRINGS, COLO. (April 26, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the ILLUMENATE Global Study at the Charing Cross Symposium in Lond
April 26, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Employe
April 22, 2016	DEF 14A	Spectranetics 2016 PROXY STATEMENT DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 1, 2016	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Stacy McMahan, Paul Gardon, and Robert McCormack signing singly, the undersigned's true and lawful attorney-in-fact to: 1.
March 24, 2016	8-K	Spectranetics 8-K 2016 UDO APPOINTMENT (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Emp
March 24, 2016	EX-99.1	Spectranetics Names Udo Scheiner as Senior Vice President, International Operations Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Names Udo Scheiner as Senior Vice President, International Operations COLORADO SPRINGS, COLO. (March 24, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced that Udo Scheiner has been named Senior Vice President, International Operations, effective March 23 rd , 2016. In this role, Mr. Scheiner will report directly to Scott
March 2, 2016	EX-12	COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) EXHIBIT 12 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2015 2014 2013 2012 2011 Earnings (loss): (Loss) income before income taxes $ (58,748 ) $ (41,223 ) $ 410 $ 2,960 $ 1,125 Fixed charges to add to earnings: Interest expense 6,883 3,546 58 63 60 Amortization of debt issuance costs 993 562 ? ? ? Rent interest factor (1) 905 528 477 395 410 Total fixed charges 8,781 4,636 535 458 470 (Loss) earnings before income taxes and fixed charges $ (49,967 ) $ (36,587 ) $ 945 $ 3,418 $ 1,595 Ratio of earnings to fixed charges (2) (5.
March 2, 2016	POS AM	Spectranetics POS AM Table of Contents As filed with the Securities and Exchange Commission on March 2, 2016 Registration No.
February 26, 2016	EX-12.1	COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2015 2014 2013 2012 2011 Earnings (loss): (Loss) income before income taxes $ (58,748 ) $ (41,223 ) $ 410 $ 2,960 $ 1,125 Fixed charges to add to ear Exhibit 12.1 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2015 2014 2013 2012 2011 Earnings (loss): (Loss) income before income taxes $ (58,748 ) $ (41,223 ) $ 410 $ 2,960 $ 1,125 Fixed charges to add to earnings: Interest expense 6,883 3,546 58 63 60 Amortization of debt issuance costs 993 562 — — — Rent interest factor (1) 905 528 477 395 4
February 26, 2016	EX-21.1	SUBSIDIARIES OF THE REGISTRANT THE SPECTRANETICS CORPORATION ANGIOSCORE INC. Jurisdiction: Delaware SPNC AUSTRALIA PTY LTD Jurisdiction: Australia SPECTRANETICS INTERNATIONAL B.V. Jurisdiction: The Netherlands SPECTRANETICS II B.V. Jurisdiction: The EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT THE SPECTRANETICS CORPORATION SUBSIDIARIES ANGIOSCORE INC. Jurisdiction: Delaware SPNC AUSTRALIA PTY LTD Jurisdiction: Australia SPECTRANETICS INTERNATIONAL B.V. Jurisdiction: The Netherlands SPECTRANETICS II B.V. Jurisdiction: The Netherlands Subsidiary of Spectranetics International B.V. SPECTRANETICS DEUTSCHLAND GMBH Jurisdiction: Germany Subsidiary o
February 26, 2016	EX-10.89	(Triple Net) Exhibit 10.89 LEASE (Triple Net) This Lease (Lease) is made and entered into by and between the Landlord and Tenant named below, who agree as follows: PART I SUMMARY OF BASIC LEASE TERMS The basic terms of this Lease are: 1. Date of Lease: June 2, 2015 (For references purposes.) 2. Landlord: Brandin Court Associates, LLC, a California limited liability company 3. Tenant: The Spectranetics Corporat
February 26, 2016	10-K	SPNC / Spectranetics Corp. (The) 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-19711 THE SPECTRANETICS CORPORATION (Exac
February 25, 2016	EX-12	COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) EX-12 3 a16-50651ex12.htm EX-12 EXHIBIT 12 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (in thousands) Nine months ended September 30, Fiscal Years 2015 2014 2013 2012 2011 2010 Earnings: Income (loss) before income taxes $ (48,571 ) $ (41,223 ) $ 410 $ 2,960 $ 1,125 $ (6,831 ) Fixed charges to add to earnings: Interest expense(1) 5,432 4,108 58 63 60 12 Rent interest factor(2) 674 528 477 39
February 25, 2016	POSASR	Spectranetics POSASR Table of Contents As filed with the Securities and Exchange Commission on February 25, 2016 Registration No.
February 25, 2016	8-K	Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS
February 25, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Empl
February 25, 2016	EX-99.1	Spectranetics Achieves Fourth Quarter 2015 Revenue of $65.2 million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Achieves Fourth Quarter 2015 Revenue of $65.2 million COLORADO SPRINGS, Colo. (February 25, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the three months and year ended December 31, 2015 . Highlights of the quarter, all compared with the three months ended December 31, 2014 include: • Revenue of $
February 16, 2016	SC 13G	SPNC / Spectranetics Corp. (The) / Arrowpoint Asset Management, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 16, 2016	SC 13G/A	SPNC / Spectranetics Corp. (The) / Point72 Asset Management, L.P. - SCHEDULE 13G/A, #1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* THE SPECTRANETICS CORPORATION (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa
February 16, 2016	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 p16244259b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behal
February 12, 2016	SC 13G/A	Spectranetics AMENDMENT NO.3 TO SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares) Amendment No.3 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* The Spectranetics Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
February 8, 2016	8-K	Spectranetics 8-K BRIDGE FDA CLEARANCE (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS E
February 8, 2016	EX-99.1	Spectranetics Receives FDA 510(k) Clearance for Bridge™ Occlusion Balloon for Lead Extraction Procedures Life-Saving Technology Designed for Safety, Stability and Procedural Control Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Receives FDA 510(k) Clearance for Bridge? Occlusion Balloon for Lead Extraction Procedures Life-Saving Technology Designed for Safety, Stability and Procedural Control COLORADO SPRINGS, COLO. (Feb. 8, 2016) - The Spectranetics Corporation (NASDAQ: SPNC) today announced U.S. Food and Drug Administration (FDA) Premarket Notification 510(k) cle
February 8, 2016	SC 13G	SPNC / Spectranetics Corp. (The) / OAK RIDGE INVESTMENTS LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Spectranetics Corp (Name of Issuer) Common Stock (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
February 5, 2016	SC 13G	SPNC / Spectranetics Corp. (The) / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SPECTRANETICS CORP (Name of Issuer) Common (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
January 11, 2016	8-K	Spectranetics 8-K 2016 SPNC MANAGEMENT PRESENTATION (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2016 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS E
January 11, 2016	EX-99.1	A CLEAR MISSION A Look Ahead Management Presentation January 2016 2 \| © 2016 Spectranetics All Rights Reserved. Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 193 a2016managementpresentat A CLEAR MISSION A Look Ahead Management Presentation January 2016 2 \| ? 2016 Spectranetics All Rights Reserved.
December 7, 2015	EX-99.1	Spectranetics Announces Debt Financing EX-99.1 4 a15-245841ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release Spectranetics Announces Debt Financing COLORADO SPRINGS, Colo., December 7, 2015 — The Spectranetics Corporation (NASDAQ: SPNC ) announced today that it has completed the refinancing of its outstanding debt and closed on a new $110 million senior secured credit facility led by Midcap Financial and Silicon Valley Bank. The ne
December 7, 2015	EX-10.2	REVOLVING CREDIT AND SECURITY AGREEMENT dated as of December 7, 2015 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, MIDCAP F Exhibit 10.2 Execution Version REVOLVING CREDIT AND SECURITY AGREEMENT dated as of December 7, 2015 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO CREDIT AND SECU
December 7, 2015	EX-10.1	TERM CREDIT AND SECURITY AGREEMENT dated as of December 7, 2015 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, MIDCAP FINANC Exhibit 10.1 Execution Version TERM CREDIT AND SECURITY AGREEMENT dated as of December 7, 2015 by and among THE SPECTRANETICS CORPORATION ANGIOSCORE INC. and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE ADDITIONAL LENDERS FROM TIME TO TIME PARTY HERETO CREDIT AND SECURITY
December 7, 2015	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2015 The Spectranetic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-19711 (Commission Fil
November 13, 2015	EX-99.1	Spectranetics Announces FDA Clearance of Turbo-Power™ Laser Atherectomy Catheter, Only Indicated Atherectomy Device for Treatment of In-Stent Restenosis Turbo-Power™ is backed by Level 1 clinical data proving clinical superiority, maximal luminal gai Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Announces FDA Clearance of Turbo-Power? Laser Atherectomy Catheter, Only Indicated Atherectomy Device for Treatment of In-Stent Restenosis Turbo-Power? is backed by Level 1 clinical data proving clinical superiority, maximal luminal gain; drives next-generation standard of care in ISR $350M domestic, $750M global market COLORADO SPRINGS, COL
November 13, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Empl
November 2, 2015	8-K	Spectranetics 8-K 2015 FREMONT LEASE (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS E
October 29, 2015	EX-10.1	Position: Chief Financial Officer Start Date: September 28, 2015 Reporting to: Scott Drake, Chief Executive Officer Compensation: You will be an exempt employee. Your gross bi-weekly salary will be $16,730.76 or $435,000.00 annually. Annual Bonus: Yo [Letterhead of The Spectranetics Corporation] August 21, 2015 Dear Stacy: We are pleased to offer you the Chief Financial Officer position with the Spectranetics Corporation (the ?Company,? ?we,? or ?us?) as a regular, full-time, exempt employee.
October 29, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 0-19711 The
October 22, 2015	8-K	Spectranetics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS E
October 22, 2015	SC 13G/A	SPNC / Spectranetics Corp. (The) / Visium Asset Management, LP - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment Amendment No. 2 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* The Spectranetics Corporation (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 84760C107 (CUSIP Number) October 13, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
October 22, 2015	EX-99.1	Spectranetics Achieves Third Quarter 2015 Revenue of $61.7 Million Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE Spectranetics Achieves Third Quarter 2015 Revenue of $61.7 Million COLORADO SPRINGS, Colo. (October 22, 2015) - The Spectranetics Corporation (NASDAQ: SPNC) today reported financial results for the three and nine months ended September 30, 2015. Highlights of the quarter, all compared with the three months ended September 30, 2014 include: ? Revenue of $6
October 9, 2015	SC 13G	SPNC / Spectranetics Corp. (The) / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* THE SPECTRANETICS CORPORATION (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 84760C107 (CUSIP Number) October 8, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
October 9, 2015	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 s15471132b.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behal
September 30, 2015	EX-24	EX-24 POWER OF ATTORNEY The undersigned hereby constitutes and appoints each of Paul Gardon and Jeffrey Sherman signing singly, the undersigned's true and lawful attorney-in-fact to: 1.
September 30, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] [email protected] Exhibit Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] [email protected] For Immediate Release Jury in Federal Court in California Finds Against AngioScore?s Patent Infringement Claims COLORADO SPRINGS, Colo. (September 30, 2015) - The Spectranetics Corporation (NASDAQ:
September 30, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Emp
August 28, 2015	8-K	Spectranetics 8-K 2015 SECURITIES LAWSUIT (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Em
August 27, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] [email protected] Spectranetics Names Stacy McMahan Chief Fina EX-99.1 2 ex99-1cfohirepressrelease.htm EXHIBIT 99.1 PRESS RELEASE Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] [email protected] Spectranetics Names Stacy McMahan Chief Financial Officer COLORADO SPRINGS, Colo. (August 27, 2015) - The Spectran
August 27, 2015	8-K	Spectranetics 8-K NEW CFO (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Em
July 30, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 spectranetics10qq22015.htm 10-Q Q2 2015 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD F
July 30, 2015	EX-10.2	STANDARD FORM INDUSTRIAL BUILDING LEASE Exhibit 10.2 STANDARD FORM INDUSTRIAL BUILDING LEASE 1.BASIC TERMS. This Section 1 contains the Basic Terms of this lease (this ?Lease?) between Landlord and Tenant, as each is named below. Other Sections of the Lease referred to in this Section 1 explain and define the Basic Terms and are to be read in conjunction with the Basic Terms. 1.1 Effective Date of Lease: March 31, 2015. 1.2 Landlord: Pe
July 23, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] 2015 Ex99.1 Q2 Earnings Release Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] FOR IMMEDIATE RELEASE Spectranetics Reports Second Quarter Financial Results Revises 2015 Outlook COLORADO SPRINGS, Colo. (July 23, 2015) - The Spectranetics Corporation
July 23, 2015	8-K	Spectranetics 8-K (Current Report/Significant Event) 2015 8K Q2 Earnings Release UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 2, 2015	8-K	Spectranetics 8-K TRIREME (Current Report/Significant Event) 8-K 2015 TriReme UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commissi
July 2, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] EX-99.1 2 ex9912015trireme.htm EXHIBIT 99.1 Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] FOR IMMEDIATE RELEASE Federal Court in California Awards AngioScore $20 Million Plus Disgorgement in Breach of Fiduciary Duty Case COLORADO SPRINGS, Colo. (J
June 29, 2015	EX-10.1	THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT Exhibit 10.1 THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT THIS THIRD AMENDMENT (this ?Amendment?), dated June 26, 2015, is entered into by and between WELLS FARGO BANK, NATIONAL ASSOCIATION (?Wells Fargo?), and THE SPECTRANETICS CORPORATION, a Delaware corporation (?Company?). RECITALS Company and Wells Fargo are parties to a Credit and Security Agreement dated February 25, 2011 (as amended fr
June 29, 2015	8-K	Spectranetics 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-19711 (Commission File N
June 12, 2015	8-K	Spectranetics 8-K SHAREHOLDER MEETING VOTE (Current Report/Significant Event) 2015 8-K SH meeting vote UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 29, 2015	SD	Spectranetics SD 2014 2014 Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 9965 Federal Drive Colorado Springs, Colorado 80921 (Add
May 29, 2015	EX-1.01	The Spectranetics Corporation Conflict Minerals Report For reporting period from January 1, 2014 to December 31, 2014 EX-1.01 2 a2014formsdex101.htm EXHIBIT 1.01 Exhibit 1.01 The Spectranetics Corporation Conflict Minerals Report For reporting period from January 1, 2014 to December 31, 2014 I. Introduction This Conflict Minerals Report (the “Report”) of The Spectranetics Corporation (the “Company,” “we,” “us,” or “our”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Secur
May 27, 2015	8-K	Spectranetics 8-K 2015 10B5-1 PLAN TERMINATION (Current Report/Significant Event) 8-K 2015 10b5-1 Plan Termination UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 8, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 0-19711 The Spec
April 29, 2015	8-K	Spectranetics 8-K 2015 PRESENTATION (Current Report/Significant Event) 8-K 2015 Mgt Presentation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 29, 2015	EX-99.1	A CLEAR MISSION The Road Ahead Management Presentation April 2015 Exhibit 99.1 2 \| © 2015 Spectranetics All Rights Reserved. Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securiti spncinvestorslidesmay201 A CLEAR MISSION The Road Ahead Management Presentation April 2015 Exhibit 99.
April 24, 2015	DEF 14A	Spectranetics 2015 PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
April 23, 2015	EX-99.2	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] 2015 Ex99.2 BTK Press Release Exhibit 99.2 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] FOR IMMEDIATE RELEASE Spectranetics Accelerates Investment in Stellarex TM Drug-Coated Balloon Platform for Treatment of Below the Knee (BTK) Peripheral Vascular Disease B
April 23, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] 2015 Ex99.1 Q1 Earnings Release Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] FOR IMMEDIATE RELEASE Spectranetics Achieves First Quarter 2015 Revenue of $57.4 Million Expands Stellarex? Program to Below the Knee Market Updates 2015 Outlook COLORAD
April 23, 2015	8-K	Spectranetics 8-K (Current Report/Significant Event) 2015 8K Q1 Earnings Release UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 19, 2015	EX-99.1	Spectranetics Announces Chief Financial Officer Transition Guy Childs to Remain Officer of the Company Ex 99-1 CFO Press Release Exhibit 99.1 CONTACT: The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] [email protected] FOR IMMEDIATE RELEASE Spectranetics Announces Chief Financial Officer Transition Guy Childs to Remain Officer of the Company COLORADO SPRINGS, Colo., March 18, 2015 - The Spectran
March 19, 2015	8-K	Spectranetics 8-K (Current Report/Significant Event) 8-K 2015 CFO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission
March 13, 2015	EX-24	EX-24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Guy Childs, Paul Gardon, and Jeffrey Sherman signing singly, the undersigned's true and lawful attorney-in-fact to: 1.
March 12, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] EX 99.1 2015 New Director PR Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] FOR IMMEDIATE RELEASE Spectranetics Appoints Todd C. Schermerhorn as Director COLORADO SPRINGS, Colo. (March 12, 2015) - The Spectranetics Corporation (NASDAQ: SPNC) today
March 12, 2015	8-K	Spectranetics 8-K (Current Report/Significant Event) 8-K 2015 New Director UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 27, 2015	EX-10.81	FORM OF SEVERANCE AGREEMENT Exhibit 10.81 FORM OF SEVERANCE AGREEMENT This SEVERANCE AGREEMENT (the ?Agreement?) is made as of the 6th day of January, 2015 (the ?Effective Date?) by and between The Spectranetics Corporation, a Delaware corporation (the ?Company?), and [Guy Childs][Shahriar Matin] (the ?Executive?). Recitals A. Executive serves as the [Chief Financial Officer] [Chief Operating Officer] of the Company; B. The
February 27, 2015	EX-10.82	FORM OF SEVERANCE AGREEMENT Exhibit 10.82 FORM OF SEVERANCE AGREEMENT This SEVERANCE AGREEMENT (the ?Agreement?) is made as of the 6th day of January, 2015 (the ?Effective Date?) by and between The Spectranetics Corporation, a Delaware corporation (the ?Company?), and (the ?Executive?). Recitals A. Executive serves as the Vice President, of the Company; B. The Company believes that it is in the best interests of the Company
February 27, 2015	EX-10.84	PRODUCT SUPPLY AGREEMENT Exhibit 10.84 PRODUCT SUPPLY AGREEMENT This PRODUCT SUPPLY AGREEMENT (this ?Agreement?) is made and entered into effective as of January 27, 2015 (the ?Effective Date?), by and between Covidien LP, a limited partnership registered in the State of Delaware (?Supplier?), and The Spectranetics Corporation, a Delaware corporation (?Purchaser?). Purchaser and Supplier are sometimes referred to herein i
February 27, 2015	EX-12.1	COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2014 2013 2012 2011 2010 Earnings (losses): (Loss) income before income taxes $ (41,223 ) $ 410 $ 2,960 $ 1,125 $ (6,831 ) Fixed charges to add to ea Exhibit 12.1 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (Unaudited - in thousands) Year ended December 31, 2014 2013 2012 2011 2010 Earnings (losses): (Loss) income before income taxes $ (41,223 ) $ 410 $ 2,960 $ 1,125 $ (6,831 ) Fixed charges to add to earnings: Interest expense 3,546 58 63 60 12 Amortization of debt issuance costs 562 — — — — Rent interest factor (1) 528 477 395 410 394 T
February 27, 2015	EX-10.80	SEVERANCE AGREEMENT Exhibit 10.80 SEVERANCE AGREEMENT This SEVERANCE AGREEMENT (the ?Agreement?) is made as of the 6th day of January, 2015 (the ?Effective Date?) by and between The Spectranetics Corporation, a Delaware corporation (the ?Company?), and Scott Drake (the ?Executive?). Recitals A. Executive serves as the President and Chief Executive Officer of the Company; B. The Company believes that it is in the best
February 27, 2015	EX-21.1	SUBSIDIARIES OF THE REGISTRANT THE SPECTRANETICS CORPORATION ANGIOSCORE INC. Jurisdiction: Delaware SPNC AUSTRALIA PTY LTD Jurisdiction: Australia SPECTRANETICS INTERNATIONAL B.V. Jurisdiction: The Netherlands SPECTRANETICS II B.V. Jurisdiction: The EX-21.1 9 ex2112014.htm SUBSIDIARIES EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT THE SPECTRANETICS CORPORATION SUBSIDIARIES ANGIOSCORE INC. Jurisdiction: Delaware SPNC AUSTRALIA PTY LTD Jurisdiction: Australia SPECTRANETICS INTERNATIONAL B.V. Jurisdiction: The Netherlands SPECTRANETICS II B.V. Jurisdiction: The Netherlands Subsidiary of Spectranetics International B.V. SPECTRANETICS DEUTSCHLAND GM
February 27, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 1 10-K 1 spnc10k12-31x2014.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-19711 T
February 27, 2015	EX-10.85	TRANSITION SERVICES AGREEMENT Exhibit 10.85 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?) is made and entered into as of the 27th day of January, 2015, by and between Covidien LP, a Delaware limited partnership (?Seller?), and The Spectranetics Corporation, a Delaware corporation (?Purchaser? and, together with Seller, each a ?Party? and collectively, the ?Parties?). RECITALS WHEREAS, purs
February 27, 2015	EX-10.83	ASSET PURCHASE AGREEMENT by and between COVIDIEN LP and THE SPECTRANETICS CORPORATION Dated as of October 31, 2014 Exhibit 10.83 ASSET PURCHASE AGREEMENT by and between COVIDIEN LP and THE SPECTRANETICS CORPORATION Dated as of October 31, 2014 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1.01 Definitions 2 1.02 Interpretation and Rules of Construction 13 ARTICLE II PURCHASE AND SALE 2.01 Purchase and Sale of Assets 13 2.02 Assumption and Exclusion of Liabilities 16 2.03 Consents 18 2.04 Purchase Price; Allocation o
February 19, 2015	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2015 The Spectranetics Corporation (Exact name of registrant as specified in its charter) Delaware 000-19711 84-0997049 (State or other jurisdiction (Commission (IRS Empl
February 19, 2015	EX-99.1	COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] Exhibit 99.1 COMPANY CONTACT INVESTOR CONTACT The Spectranetics Corporation Westwicke Partners Guy Childs, Chief Financial Officer Lynn Pieper (719) 633-8333 (415) 202-5678 [email protected] FOR IMMEDIATE RELEASE Spectranetics Achieves Fourth Quarter 2014 Revenue of $63.0 Million Stellarex DCB Acquisition Closed and Stellarex Launched in Europe Updates 2015 Outlook COLORADO SPRINGS, Colo.
February 12, 2015	SC 13G/A	SPNC / Spectranetics Corp. (The) / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* The Spectranetics Corporation (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 84760C107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

SPNC / Spectranetics Corp. (The) - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)